Bractoppin
CAS No. 2290527-07-8
Bractoppin ( —— )
产品货号. M24041 CAS No. 2290527-07-8
Bractoppin is a drug-like inhibitor of phosphopeptide recognition by the human BRCA1 tandem (t)BRCT domain (IC50 = 0.074 μM), which selectively inhibits substrate binding with nanomolar potency in vitro.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥632 | 有现货 |
|
5MG | ¥1021 | 有现货 |
|
10MG | ¥1677 | 有现货 |
|
25MG | ¥3629 | 有现货 |
|
50MG | ¥5330 | 有现货 |
|
100MG | ¥7598 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Bractoppin
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Bractoppin is a drug-like inhibitor of phosphopeptide recognition by the human BRCA1 tandem (t)BRCT domain (IC50 = 0.074 μM), which selectively inhibits substrate binding with nanomolar potency in vitro.
-
产品描述Bractoppin is a drug-like inhibitor of phosphopeptide recognition by the human BRCA1 tandem (t)BRCT domain (IC50 = 0.074 μM), which selectively inhibits substrate binding with nanomolar potency in vitro. Structure-activity exploration suggests that Bractoppin engages BRCA1 tBRCT residues recognizing pSer in the consensus motif, pSer-Pro-Thr-Phe, plus an abutting hydrophobic pocket that is distinct in structurally related BRCT domains, conferring selectivity.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Others
-
研究领域——
-
适应症——
化学信息
-
CAS Number2290527-07-8
-
分子量414.5
-
分子式C25H23FN4O
-
纯度>98% (HPLC)
-
溶解度DMSO:10 mM
-
SMILESO=C(N1CCN(CC2=CC=CC=C2F)CC1)C3=CC=C4NC(C5=CC=CC=C5)=NC4=C3
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Periasamy J , Kurdekar V , Jasti S , et al. Targeting Phosphopeptide Recognition by the Human BRCA1 Tandem BRCT Domain to Interrupt BRCA1-Dependent Signaling[J]. Cell Chemical Biology, 2018:S245194561830076X.
产品手册
关联产品
-
Methyl nomilinate
Methyl nomilinate from citrus can modulate cell cycle regulators to induce cytotoxicity in human colon cancer (SW480) cells in vitro.
-
Methyl piperate
The fruits of Piper nigrum L.
-
Amaranth
Amaranth as a potential component of lifestyle modification to improve cardiovascular risk profiles by modifying cardiovascular risk factors such as cholesterol diabetes and hypertension.